Allworth Financial LP Makes New Investment in Bristol Myers Squibb Company $BMY
Allworth Financial LP has made a new investment in Bristol Myers Squibb Company, acquiring 129,525 shares valued at approximately $7.46 million. This investment comes as other institutional investors have also adjusted their positions in the biopharmaceutical company. Bristol Myers Squibb recently reported strong quarterly earnings, exceeding analyst expectations, and announced a quarterly dividend.
Bristol-Myers Squibb Co (BMY) Shares Fall 3.2% -- GF Value Says Still Overvalued
Bristol-Myers Squibb Co (BMY) shares dropped 3.2% to $65.47, with GuruFocus's GF Value indicating the stock is 15.9% overvalued compared to its intrinsic value of $56.49. Despite a P/E ratio below its historical median, its GF Score of 71/100 points to strong profitability but weaker growth and momentum. Insider selling further raises concerns about the company's near-term prospects.
Bristol-Myers Squibb Co Stock (BMY) Closed Down by 3.17% on Aug 20: Facts Behind the Movement
Bristol-Myers Squibb Co (BMY) stock closed down by 3.17% on August 20, primarily due to profit-taking after a multi-week rally and concerns over looming patent expirations on legacy treatments. Despite strong Q2 earnings and regulatory approvals, investors are balancing these positives against long-term structural risks, including potential revenue contraction and significant debt. Technical indicators suggest mixed signals, while fundamental analysis highlights the company's substantial revenue and profit within the Pharmaceuticals & Medical Research industry.
Bristol Myers Squibb Co. stock underperforms Thursday when compared to competitors
Shares of Bristol Myers Squibb Co. (BMY) fell 3.17% on Thursday, closing at $65.47, amidst a broad market decline where the S&P 500 Index dropped 0.87% and the Dow Jones Industrial Average fell 1.32%. This performance marked an underperformance compared to its competitors and ended a three-day winning streak for the stock.
Is Janux Therapeutics (JANX) Narrowing Losses Enough To Shift Its Long-Term Risk Profile?
Janux Therapeutics (JANX) reported reduced net losses of US$21.97 million for Q2 2026 and US$46.33 million for the six-month period, indicating more efficient cost management. While these narrowing losses ease near-term financing concerns, Janux remains a pre-profit, high-spend biotech company heavily reliant on future clinical trial outcomes and its partnership with Bristol Myers Squibb. Investors are advised to consider the company's valuation report, which suggests an inflated share price compared to its estimated value.
ASP Isotopes at emerging growth conference: push to commercialize key materials
ASP Isotopes (ASPI) presented its strategy at the Emerging Growth Conference, focusing on transitioning multiple development projects into commercial operations. The company aims to commercialize its helium, isotope, and nuclear fuel businesses within the next six months, despite significant stock volatility and supply chain challenges. Key initiatives include starting commercial production for various isotopes and the Renergen helium/LNG project, with expectations for revenue and free cash flow generation.
UBS reiterates Buy on Bristol-Myers Squibb stock, $80 target
UBS has reiterated a Buy rating on Bristol-Myers Squibb (BMY) with an $80 price target, citing upcoming Phase III trial results for several key programs, including Milvexian and admilparant. These pipeline assets are expected to generate billions in sales and help offset potential losses from expiring patents. The outlook is further supported by analyst upgrades and recent accelerated approval for Zenbexus.
Why Bristol Myers, Johnson & Johnson and More Are Watching Seaport After IPO
Seaport Therapeutics (SPTX) recently went public and is being closely watched by major pharmaceutical companies like Bristol Myers Squibb and Johnson & Johnson due to its innovative Glyph prodrug platform. The company, which currently has no product revenue, has 24 drug candidates with its lead asset, GlyphAllo, in Phase 2b trials for MDD, with results expected in the first half of 2027. Its potential for acquisition is high, especially given the history of its CEO, Daphne Zohar, whose previous company Karuna Therapeutics was acquired by Bristol Myers Squibb.
Chai tees up Bristol Myers Squibb AI antibody discovery collab
Chai Discovery, an AI drug discovery firm, has partnered with Bristol Myers Squibb (BMS) to accelerate the discovery of therapeutic antibodies using artificial intelligence. This collaboration follows Chai's recent $400 million Series C funding round and adds BMS to a list of other Big Pharma partners including Eli Lilly, Pfizer, and Novartis. While financial details were not disclosed, BMS will leverage Chai's AI models and platform capabilities for antibody discovery.
Chai Discovery Announces Collaboration with Bristol Myers Squibb to Advance AI-Driven Antibody Discovery
Chai Discovery has partnered with Bristol Myers Squibb to use AI for discovering therapeutic antibodies. Bristol Myers Squibb will utilize Chai's AI models, including molecular folding and design, to accelerate the discovery of antibody candidates across its portfolio and build an AI-powered discovery system. This collaboration aims to speed up the process from concept to viable therapeutic candidates by leveraging AI to predict and reprogram molecular interactions.
IDEAYA Biosciences (IDYA) Is Up 5.2% After Genentech KRAS G12D Trial Collaboration News - Has The Bull Case Changed?
IDEAYA Biosciences has announced a clinical collaboration with Genentech to test its investigational MTA-cooperative PRMT5 inhibitor, IDE892, in combination with Genentech's KRAS G12D inhibitor GDC-7035 for a specific type of pancreatic cancer. This partnership is seen as external validation for IDEAYA's precision oncology platform and its focus on combination regimens in MTAP-deleted tumors. While the collaboration diversifies partnership support and strengthens confidence in IDEAYA's strategy, it also introduces another early-stage program that will require significant time and capital.
Knuff & Co LLC Acquires New Holdings in Bristol Myers Squibb Company $BMY
Knuff & Co LLC has acquired 16,438 shares of Bristol Myers Squibb (NYSE:BMY) during the second quarter, valued at approximately $947,000, as other institutional investors also adjusted their holdings. The biopharmaceutical company reported strong Q2 earnings, beating analyst estimates with $2.04 EPS and $12.97 billion in revenue, and issued optimistic fiscal 2026 EPS guidance. Analysts maintain a "Moderate Buy" consensus rating with an average price target of $66.06, with some firms raising targets to $73–$75.
Edmond DE Rothschild Holding S.A. Acquires Shares of 113,537 Bristol Myers Squibb Company $BMY
Edmond DE Rothschild Holding S.A. recently acquired 113,537 shares of Bristol Myers Squibb Company (NYSE:BMY) for approximately $6,542,000 in the second quarter. Other institutional investors also adjusted their positions in BMY, with Lazard Asset Management LLC significantly increasing its stake. The biopharmaceutical company received a "Moderate Buy" consensus rating from analysts, with an average price target of $66.06.
Amgen Inc. $AMGN Shares Sold by Danske Bank A S
Danske Bank A S reduced its holdings in Amgen Inc. by 6.8% in the second quarter, selling 29,273 shares, though other institutional investors like Norges Bank and BlackRock Inc. significantly increased their stakes. The article also details recent analyst ratings, Amgen's strong financial performance including a raised dividend, and insider share sales by SVP Nancy A. Grygiel and SVP Rachna Khosla.
Abacus FCF Advisors LLC Makes New $13.11 Million Investment in Bristol Myers Squibb Company $BMY
Abacus FCF Advisors LLC has made a new investment of $13.11 million in Bristol Myers Squibb Company, acquiring 227,584 shares. This investment makes Bristol Myers Squibb the 11th largest position in Abacus FCF Advisors LLC's portfolio, representing approximately 2.4% of its holdings. Other institutional investors have also adjusted their stakes in the biopharmaceutical company, which recently reported strong quarterly earnings and declared a quarterly dividend.
AstraZeneca PLC : Goldman Sachs reaffirms its Buy rating
Goldman Sachs has reaffirmed its Buy rating for AstraZeneca PLC, with analyst Rajan Sharma issuing a research note advising clients to purchase the stock. The target price for AstraZeneca's shares has been slightly adjusted upward from 16070 GBX to 16300 GBX.
Pfizer (PFE) Reaches Deal Covering About 5,000 Federal Lawsuit Claims
Pfizer (NYSE:PFE) has established a settlement program aimed at resolving a significant portion of federal lawsuits concerning Depo-Provera intracranial meningioma, potentially covering around 5,000 of over 6,200 pending claims. This confidential agreement is a crucial legal development that could impact Pfizer's litigation reserves, risk profile, and public perception. Investors will be looking to future financial reports for clarity on the financial implications and whether the costs are within existing expectations.
Is Bristol-Myers Squibb (BMY) Fully Priced As FDA Approval And $2.3b Expansion Lift Outlook?
Bristol-Myers Squibb (BMY) recently received FDA approval for its new multiple myeloma drug ZENBEXUS and announced a US$2.3 billion investment in a new manufacturing campus. Despite a strong recent share price performance, analysts suggest the stock is 7.4% overvalued compared to a fair value of $62.96, primarily due to anticipated revenue decline despite rising profit margins. However, its P/E ratio of 14.9x is significantly lower than peers, raising questions about a potential re-rating.
Jefferies sets strong price target on upstart cancer stock
Jefferies has initiated coverage on Freenome (FRNM), a cancer-screening company, with a "Buy" rating and a $17 price target, suggesting a significant upside. The bullish outlook is based on Freenome's transition from a research company to a commercial-stage entity, its partnerships with Abbott and Roche, and its pipeline of cancer screening tests beyond its initial colorectal cancer product. While the stock offers high-risk, high-reward potential, investors are advised to wait for sales data from the upcoming fall launch and keep positions small due to the company's early stage and unprofitability.
AstraZeneca PLC Stock (AZN) Moved Up by 3.40% on Aug 19: What Signal Does It Send?
AstraZeneca (AZN) stock rose by 3.40% due to positive Phase III oncology trial results for Tagrisso/Orpathys and Enhertu, which garnered bullish analyst commentary. Fading rumors of a merger with Bristol Myers Squibb also shifted investor focus back to AstraZeneca's strong organic growth and robust drug portfolio. The company reported annual revenue of $58.74 billion and a net profit of $10.22 billion.
Cytokinetics Gains 20.5% YTD: Buy, Sell or Hold the Stock?
Cytokinetics (CYTK) has seen a 20.5% year-to-date gain following the FDA approval of its drug Myqorzo for obstructive hypertrophic cardiomyopathy (oHCM). The drug is experiencing strong commercial adoption in the U.S. and has launched in Europe, with further market expansion anticipated. While the company has a strong financial position and other pipeline candidates, its heavy reliance on Myqorzo and competition from Bristol Myers Squibb's Camzyos suggest a "Hold" rating for existing shareholders, with new investors advised to await a more attractive entry point.
Bristol Myers Squibb Co. stock outperforms competitors on strong trading day
Bristol Myers Squibb Co. (BMY) stock gained 2.36% on Wednesday, closing at $67.61, outperforming the broader market. This marks the third consecutive day of gains for the company's stock. The S&P 500 Index and the Dow Jones Industrial Average also saw modest gains during the trading session.
Bristol Myers Squibb to build $2.3B manufacturing campus in Houston
Bristol Myers Squibb announced a $2.3 billion investment to construct a 600,000-square-foot high-tech medicine manufacturing campus in Houston. This project, part of a larger domestic growth strategy, is expected to create about 500 jobs and will produce small molecules, biologics, and antibody-drug conjugates. The modular design will allow for flexibility and future integration of digital and automation advancements, making Houston a key hub in the company's manufacturing network.
Hematogenix's MM MRD Assay Underpins FDA Accelerated Approval of Bristol Myers Squibb's ZENBEXUS™, the First Approved CELMoD Therapy for Multiple Myeloma
Hematogenix's proprietary Multiple Myeloma MRD (MM MRD) assay played a crucial role in the FDA's accelerated approval of Bristol Myers Squibb's ZENBEXUS™ (iberdomide), the first CELMoD therapy for multiple myeloma. The assay measured the primary efficacy endpoint of MRD-negative complete response in the Phase 3 EXCALIBER-RRMM trial, demonstrating a statistically significant improvement for ZENBEXUS. This highlights Hematogenix's expertise in providing regulatory-grade assay methodology for registrational oncology trials, particularly as MRD negativity becomes a key measure of treatment success in multiple myeloma.
Hematogenix's MM MRD Assay Underpins FDA Accelerated Approval of Bristol Myers Squibb's ZENBEXUS™, the First Approved CELMoD Therapy for Multiple Myeloma
Hematogenix's proprietary Multiple Myeloma MRD (MM MRD) assay played a crucial role in the FDA's accelerated approval of Bristol Myers Squibb's ZENBEXUS™ (iberdomide), the first CELMoD therapy for multiple myeloma. The assay measured the primary efficacy endpoint, MRD-negative complete response, in the Phase 3 EXCALIBER-RRMM trial, demonstrating a statistically significant improvement with ZENBEXUS. This validation highlights Hematogenix's expertise in providing regulatory-grade assay methodologies for innovative oncology treatments.
Why Novartis, Lilly, and Bristol Myers Are Eyeing This Clinical-Stage Cancer Play
Aktis Oncology (AKTS), a clinical-stage radiopharmaceutical company with a $1.4 billion market cap, is drawing attention from major pharmaceutical companies like Novartis, Eli Lilly, and Bristol Myers Squibb due to its innovative alpha-emitting radioconjugate platform. Aktis retains full worldwide rights to its technology and has significant cash reserves, with key trial data expected in Q1 2027. The company's lead candidates target Nectin-4 and B7-H3, making it an attractive acquisition target for companies seeking to expand their oncology pipelines.
Hematogenix's MM MRD Assay Underpins FDA Accelerated Approval of Bristol Myers Squibb's ZENBEXUS™, the First Approved CELMoD Therapy for Multiple Myeloma
Hematogenix announced that its proprietary Next Generation Flow Cytometry (NGF) assay for Multiple Myeloma Minimal Residual Disease (MM MRD) was crucial in the FDA's accelerated approval of Bristol Myers Squibb's ZENBEXUS™ (iberdomide), the first approved CELMoD therapy for multiple myeloma. The assay measured the primary efficacy endpoint of MRD-negative complete response in the EXCALIBER-RRMM trial, highlighting Hematogenix's expertise in registrational oncology trials. This approval reinforces the growing importance of MRD negativity as a measure of treatment success in multiple myeloma and validates Hematogenix's specialized assay methodology.
Teva scores rare partial win in CMS price negotiation appeal
Teva Pharmaceuticals achieved a partial victory in its challenge against the Medicare drug price negotiation program, as a U.S. appeals court sent a ruling back to a lower court for review. The case concerns CMS's requirement that a generic drug must be genuinely marketed before its brand-name counterpart is excluded from negotiation. However, the court rejected Teva's separate challenge regarding the classification of its drug Austedo as a single qualifying product for price negotiations.
Bristol Myers Squibb to build $2.3B manufacturing campus in Houston
Bristol Myers Squibb announced a $2.3 billion investment to construct a high-tech medicine manufacturing campus in Houston, Texas. This 600,000-square-foot facility will create about 500 jobs and produce small molecules, biologics, and antibody-drug conjugates, enhancing the company's domestic growth strategy. The project, supported by Texas state incentives, is part of BMS's broader plan to invest $40 billion in the U.S. by 2030, reinforcing the nation's pharmaceutical supply chain.
Bristol Myers Squibb Company $BMY Holdings Trimmed by Pzena Investment Management LLC
Pzena Investment Management LLC reduced its stake in Bristol Myers Squibb Company ($BMY) by 0.5% in the second quarter, making it their 8th largest holding. Despite this trimming, other institutional investors have recently increased their holdings in BMY. The article also covers BMY's stock performance, recent earnings, dividend announcement, and updated analyst ratings, which generally recommend a "Moderate Buy" for the company.
Cytokinetics EVP research & development sells $265,370 in stock By Investing.com
Fady Ibraham Malik, EVP of Research & Development at Cytokinetics Inc., sold 3,500 shares of common stock for $265,370 on August 18, 2026, after acquiring them through non-qualified stock options. This sale follows the company's strong second-quarter financial results, driven by the success of its heart drug MYQORZO, and positive revisions to analyst estimates, despite the stock appearing overvalued by some metrics.
AstraZeneca PLC : Deutsche Bank reiterates its Sell rating
Deutsche Bank has reiterated its "Sell" rating for AstraZeneca PLC, maintaining a target price of GBX 11,500. This news comes amidst other analyst actions, with UBS reiterating a "Buy" rating for AstraZeneca on the same day. The article also provides recent news headlines related to AstraZeneca and the broader market.
Danica Pension Livsforsikringsaktieselskab Buys New Stake in Bristol Myers Squibb Company $BMY
Danica Pension Livsforsikringsaktieselskab has acquired a new stake of 165,023 shares, valued at approximately $9.5 million, in Bristol Myers Squibb Company (NYSE:BMY) during the second quarter. Other institutional investors also adjusted their positions in BMY, and the company has received a "Moderate Buy" consensus rating from analysts with a target price of $66.06. Bristol Myers Squibb reported strong quarterly earnings, surpassing analyst estimates, and announced a quarterly dividend.
Danske Bank A S Acquires Shares of 1,501,133 Bristol Myers Squibb Company $BMY
Danske Bank A S recently acquired 1,501,133 shares of Bristol Myers Squibb Company (BMY), valued at approximately $86.5 million, giving it a 0.07% stake. This comes as institutional investors collectively own 76.41% of BMY. Bristol Myers Squibb reported strong quarterly earnings, surpassing analyst estimates with $2.04 per share and a 5.7% revenue increase. The company maintains a quarterly dividend of $0.63 per share, representing a 3.8% annualized yield, and analysts hold a "Moderate Buy" consensus rating with an average price target of $66.06.
BlackRock Inc. Raises Position in Bristol Myers Squibb Company $BMY
BlackRock Inc. significantly increased its stake in Bristol Myers Squibb Company (NYSE:BMY) by 5.1% in the second quarter, now owning 180.38 million shares valued at over $10 billion. Other institutional investors also adjusted their positions, and analysts have largely maintained a "Moderate Buy" consensus rating with an average target price of $66.06 for the biopharmaceutical company. Bristol Myers Squibb reported strong quarterly earnings and revenue, exceeding consensus estimates, and recently announced a quarterly dividend of $0.63 per share.
Schrödinger (SDGR) Turns Profitable As Bristol Myers Squibb Deal Tests Its Valuation
Schrödinger (SDGR) has turned profitable in Q2 2026 and secured a new agreement with Bristol Myers Squibb to deploy its Bunsen AI co-scientist, leading to recent positive share price momentum. Despite trading at a discount to analyst targets and some fair value estimates, its P/S ratio is higher than industry averages, suggesting investors are paying a premium for future growth potential. The company's valuation hinges on the continued progress of its software and drug discovery engines, supported by increasing adoption of AI-driven modules and FDA initiatives.
Replimune Soars Over 120% as FDA Panel Backs Melanoma Therapy Ahead of August Decision
Shares of Replimune Group (REPL) surged over 120% after an FDA advisory committee voted 10 to 3 that its melanoma therapy, RP1, showed clinically meaningful efficacy. This vote reverses previous FDA rejections and sets the stage for a final regulatory decision expected by August 2, 2026. Analysts have reacted positively, with Cantor Fitzgerald upgrading the stock, and the heavily shorted company anticipates high volatility.
Halozyme Appoints Dannielle Appelhans to its Board of Directors
Halozyme Therapeutics, Inc. announced the election of Dannielle Appelhans to its Board of Directors. Ms. Appelhans brings over 20 years of executive leadership in the biotechnology and pharmaceutical industries, with significant expertise in operations, manufacturing, and supply chain management. Her experience will be a key asset as Halozyme continues to advance its drug delivery technology platforms and growth strategy.
Halozyme adds Dannielle Appelhans to board of directors
Halozyme Therapeutics, Inc. (NASDAQ:HALO) announced the appointment of Dannielle Appelhans to its board of directors. Appelhans, currently CEO of COUR Pharmaceuticals, brings extensive experience from her previous roles at Rubius Therapeutics, Inc., Novartis, McKinsey & Company, and Eli Lilly and Company. Her operational and manufacturing expertise is expected to support Halozyme's growth strategy.
Bristol Myers Squibb Co. stock underperforms Tuesday when compared to competitors despite daily gains
Bristol Myers Squibb Co. (BMY) stock saw a daily gain of 2.20% on Tuesday, closing at $66.05. Despite this increase, the stock underperformed compared to its competitors and the broader market, as the S&P 500 and Dow Jones Industrial Average both experienced declines. This marks the second consecutive day of gains for Bristol Myers Squibb Co.
Bristol Myers Squibb (BMY) Stock May Be 46% Below Fair Value As FDA Approval Lands
Bristol Myers Squibb (BMY) stock appears undervalued, with its Discounted Cash Flow (DCF) model suggesting it could be 45.6% below its intrinsic value, despite a 40.6% return over the past year. This undervaluation is supported by a P/E ratio lower than industry averages and a recent FDA accelerated approval for ZENBEXUS, which could boost future cash flows. However, a revived $6.7 billion lawsuit regarding delayed drug approvals and upcoming patent cliffs for key blockbusters like Eliquis and Opdivo present potential risks that might be weighing on investor sentiment.
Regeneron ends eye disease study after antibody shows ‘unfavorable’ risk/benefit profile
Regeneron has terminated a Phase 1/2 study of its investigational anti-inflammatory antibody, REGN7041, for non-infectious uveitis due to an "unfavorable benefit-risk assessment." This marks another clinical setback for Regeneron, following failures of itepekimab for COPD and a melanoma combo. Despite these challenges, the company, while facing pressure for M&A, has been active in strategic partnerships to build its pipeline.
Immatics (NASDAQ: IMTX) posts €120m loss funding Phase 3 melanoma push
Immatics N.V. reported a net loss of €120.3 million for the first half of 2026, widening from €110.2 million in the prior year, primarily due to increased research and development expenses for its Phase 3 SUPRAME trial of anzu-cel in melanoma. Despite the loss, the company maintains a strong cash position of €393.4 million, sufficient to fund operations for at least 12 months. Immatics is advancing its PRAME franchise, with key clinical milestones and plans for a Biologics License Application (BLA) submission for anzu-cel in 2027.
Amylyx’s bet on a GLP-1 blocker pays off
Amylyx Pharmaceuticals reported positive results from a late-stage clinical trial for avexitide, a GLP-1 blocker designed to treat dangerously low blood sugar levels in patients who have undergone bariatric surgery. The drug significantly reduced hypoglycemic events and appeared safe, leading Amylyx to plan for FDA approval by year-end. Analysts project avexitide could generate significant revenue, marking a potential comeback for the company after a previous drug failure.
49,346 Shares in Bristol Myers Squibb Company $BMY Acquired by Trust Co. of Vermont
Trust Co. of Vermont recently acquired 49,346 shares of Bristol Myers Squibb Company (NYSE:BMY), valued at approximately $2.843 million. This purchase is part of a broader trend where various institutional investors and hedge funds have adjusted their holdings in BMY, with the stock currently seeing 76.41% ownership by institutional investors. Bristol Myers Squibb reported strong quarterly earnings, surpassing analyst expectations, and has a "Moderate Buy" consensus rating from analysts with an average price target of $66.06.
TimesSquare Capital Management LLC Purchases Shares of 451,593 Xenon Pharmaceuticals Inc. $XENE
TimesSquare Capital Management LLC has acquired 451,593 shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a new position valued at approximately $27.3 million, giving them a 0.47% stake in the biopharmaceutical company. Institutional investors collectively own 95.45% of the stock. Xenon Pharmaceuticals recently reported better-than-expected quarterly adjusted EPS and maintains a "Buy" consensus rating from analysts, despite recent insider share sales.
94,816 Shares in Bristol Myers Squibb Company $BMY Purchased by Global Retirement Partners LLC
Global Retirement Partners LLC has acquired a new stake of 94,816 shares in Bristol Myers Squibb Company (NYSE:BMY), valued at approximately $5,463,000. This purchase is part of a broader trend of institutional investment in BMY, with several other major firms increasing their holdings. Analysts currently have a "Moderate Buy" rating for Bristol Myers Squibb, with a consensus price target of $66.06.
AstraZeneca's Portfolio and Pipeline Support Solid Long-Term Growth
This article from Morningstar highlights AstraZeneca's strong portfolio of patent-protected drugs and a robust developing pipeline. The author, Jay Lee, suggests that this foundation supports solid long-term growth for the company, earning it a wide economic moat. The continuous replenishment of new drugs is key to its sustained success in the pharma and biotech industry.
Bristol Myers Squibb Co. stock outperforms competitors on strong trading day
Shares of Bristol Myers Squibb Co. (BMY) rose 1.25% to $64.63 on a Monday when the broader market saw declines, with the S&P 500 Index and Dow Jones Industrial Average both falling. The stock's performance outpaced its competitors despite the overall market downturn. Bristol Myers Squibb Co. closed 5.10% below its 52-week high.
AstraZeneca scraps Phase 3 trial of new bispecific in lung cancer
AstraZeneca has terminated a Phase 3 trial for its experimental bispecific antibody drug, volrustomig, in non-small cell lung cancer. An interim data check indicated the therapy was unlikely to improve patient survival compared to standard treatment. Despite this setback, AstraZeneca plans to continue with other Phase 3 trials for volrustomig in different cancer types and remains committed to developing new lung cancer medicines.
